Member Info for Swapleber

Misery man
I have taken a company to the aim market
Have you?
I suggest nit!!

Aquae,, the nomad would make the call

I’ll have dough coming out of me ears soon enough
Hope you do too!

Another week closer to untold wealth

I have more wit in my small finger than you
You dope

Also , if you know of anyone working on universal vaccines for, for instance, flu or mosquito borne viruses...let me know. Don’t hide your light under a bushel or be selfish about it...

Do you know of any particular company that is expert in this. If so, please share, I’d like to invest ...

Reaction to successive RNS’s of a positive nature.
The fact is, IMHO, there will be a game changing RNS in the next six WEEKS
And then we can all relax....

Kt
No rns for that... not something significant
We may get a better one tho....just sayin

They have tested it on a whole 40 people!!

what i mean is nefarious behavior, to take the only company in the world with 8 challenge trials including covid off the public market place. i dare say big pharma has done (a lot) worse

Months...that’s a 300 price tag for sure...and that won’t be too far away

The only reason big pharma would buy it would be to have it in house....what a competitive advantage. Screw their competitors and they are perfectly capable of doing this.

i am putting my money on ICON as the acquiror.
Prof Buckley sold them a specialist CRO , Firecrest, some years ago and then worked with them in the c-suite....simples

For example, in an interview around this weeks news, Cathal mentioned that the customer, one of the worlds top three pharmaceutical companies, came looking for hVivo.
That kinda says a lot.

They sell services to big pharma who compete.

So a cro will pay c. 300 m for orph base business based on a secure projection of 100 million annual revenue.

Imutex will be sold for c. 500 with our share at 248 so I’m putting a value of c. 550 on the business at disposal. C. 82 pence a share. And do you know what. I’m very happy wiry that....

.

https://www.brrmedia.co.uk/broadcasts/5f2d19f5ac615d638c140add/open-orphan-new-contract-win

And will there not always be day traders churning for a few percent?

Covid challenges